A PILOT STUDY OF A STEROID SULPHATASE INHIBITOR (BN83495) IN PATIENTS WITH RASH DUE TO TREATMENT WITH AN ORAL EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR (EGFR-TKI) FOR NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Mileshkin, Linda [1 ]
Mccormack, Chris [1 ]
Michael, Michael [1 ]
Solomon, Ben [1 ]
Urban, Damien [1 ]
Link, Emma [1 ]
Cowan, Linda [1 ]
Zalcberg, John [1 ]
机构：
[1] Peter MacCallum Canc Ctr, Div Canc Med, East Melbourne, Vic, Australia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
rash; EGFR; NSCLC; supportive care;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.24-041
引用
收藏
页码：S1020 / S1020
页数：1
相关论文
共 50 条
  • [41] Treatment of brain metastases in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: the role of EGFR tyrosine kinase inhibitors
    Karachaliou, Niki
    Rosell, Rafael
    ANNALS OF PALLIATIVE MEDICINE, 2013, 2 (03) : 114 - 117
  • [42] Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis
    Lee, H. J.
    Jeong, G. H.
    Li, H.
    Kim, M. S.
    Kim, J. S.
    Park, S. J.
    Han, Y. J.
    Lee, K. H.
    Kronbichler, A.
    Hong, S. H.
    Ghayda, R. A.
    Luchini, C.
    Nottegar, A.
    Koyanagi, A.
    Smith, L.
    Jacob, L.
    Dragioti, E.
    Radua, J.
    Cargnin, S.
    Terrazzino, S.
    Thompson, T.
    Yon, D. K.
    Lee, S. W.
    Yang, J. M.
    Wasuwanich, P.
    Shin, J. I.
    Gamerith, G.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (20) : 6232 - 6244
  • [43] THE ROLE EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR IN MANAGEMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
    Mok, Tony
    ANNALS OF ONCOLOGY, 2010, 21 : 5 - 5
  • [44] Fluorescence Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer
    Martin-Fernandez, Marisa L.
    CANCERS, 2022, 14 (03)
  • [45] Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
    Lee, Jae Cheol
    Jang, Seung Hun
    Lee, Kye Young
    Kim, Young-Chul
    CANCER RESEARCH AND TREATMENT, 2013, 45 (02): : 79 - 85
  • [46] The mutation status of the epidermal growth factor receptor (EGFR) as a selection criterion for therapy with EGFR tyrosine kinase inhibitors (TKI's) in non-small cell lung cancer (NSCLC).
    Mathy, A.
    Nederlof, P.
    Boerrigter, L.
    Van 't Veer, L.
    De Jong, D.
    Baas, P.
    Burgers, S.
    Van Zandwijk, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 558S - 558S
  • [47] Phase II study of BI1482694 in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)
    Janne, P. A.
    Son, J.
    Voccia, I.
    Uttenreuther-Fischer, M.
    Park, K.
    ANNALS OF ONCOLOGY, 2015, 26 : 145 - 145
  • [48] Phase II study of BI1482694 in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)
    Sun, J.
    Wang, Y. -M.
    Duan, Y. -Z.
    ANNALS OF ONCOLOGY, 2015, 26 : 145 - 145
  • [49] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Non-Small Cell Lung Cancer With Uncommon Mutations
    Kanazu, Masaki
    Naoki, Yoko
    Shiroyama, Takayuki
    Tamiya, Motohiro
    Tamiya, Akihiro
    Omachi, Naoki
    Okishio, Kyoichi
    Suzuki, Hidekazu
    Okamoto, Norio
    Morishita, Naoko
    Hirashima, Tomonori
    Atagi, Shinji
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S318 - S318
  • [50] Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
    Choi, Yong Won
    Choi, Jin-Hyuk
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2017, 32 (03): : 422 - 428
12345